Goldman Sachs Group Inc Point Biopharma Global Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 14, 2024
BUY
$6.67 - $9.71 $1.61 Million - $2.35 Million
242,071 New
242,071 $1.61 Million
Q3 2023

Nov 14, 2023
SELL
$6.67 - $9.71 $4.78 Million - $6.97 Million
-717,388 Reduced 74.77%
242,071 $1.61 Million
Q2 2023

May 14, 2024
SELL
$6.86 - $10.86 $345,977 - $547,713
-50,434 Reduced 4.99%
959,459 $8.69 Million
Q2 2023

Aug 14, 2023
SELL
$6.86 - $10.86 $345,977 - $547,713
-50,434 Reduced 4.99%
959,459 $8.69 Million
Q1 2023

May 14, 2024
BUY
$6.78 - $8.1 $5.21 Million - $6.22 Million
768,242 Added 317.91%
1,009,893 $7.34 Million
Q1 2023

May 11, 2023
BUY
$6.78 - $8.1 $5.21 Million - $6.22 Million
768,242 Added 317.91%
1,009,893 $7.34 Million
Q4 2022

May 14, 2024
BUY
$5.72 - $9.78 $360,159 - $615,797
62,965 Added 35.24%
241,651 $1.76 Million
Q4 2022

Feb 13, 2023
BUY
$5.72 - $9.78 $360,159 - $615,797
62,965 Added 35.24%
241,651 $1.76 Million
Q3 2022

May 14, 2024
SELL
$7.24 - $10.31 $1.59 Million - $2.27 Million
-220,111 Reduced 55.19%
178,686 $1.38 Million
Q3 2022

Nov 10, 2022
SELL
$7.24 - $10.31 $1.59 Million - $2.27 Million
-220,111 Reduced 55.19%
178,686 $1.38 Million
Q2 2022

May 14, 2024
BUY
$5.6 - $9.5 $2.23 Million - $3.79 Million
398,797 New
398,797 $2.72 Million
Q2 2022

Aug 15, 2022
BUY
$5.6 - $9.5 $1.75 Million - $2.97 Million
312,692 Added 363.15%
398,797 $2.72 Million
Q1 2022

May 16, 2022
SELL
$5.46 - $8.13 $248,053 - $369,354
-45,431 Reduced 34.54%
86,105 $686,000
Q4 2021

Feb 14, 2022
BUY
$4.83 - $9.75 $635,318 - $1.28 Million
131,536 New
131,536 $737,000

Others Institutions Holding PNT

# of Institutions
1
Shares Held
20K
Call Options Held
0
Put Options Held
0
View Full List

About POINT Biopharma Global Inc.

PNT Quotes by TradingView
  • Ticker PNT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 104,025,000
  • Description
  • POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...
More about PNT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email